These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2439826)

  • 21. Bopindolol: long-term effects on blood pressure, renal function, plasma renin activity, and plasma aldosterone in mild-to-moderate essential hypertension.
    Shohat J; Modan M; Rosenfeld JB
    Fundam Clin Pharmacol; 1989; 3(1):53-8. PubMed ID: 2565862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the antihypertensive effect of a beta-blocker with the aid of daily blood pressure profiles.
    Abetel G; Karly M; Genoud G
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S77-9. PubMed ID: 2439827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bopindolol. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.
    Harron DW; Goa KL; Langtry HD
    Drugs; 1991 Jan; 41(1):130-49. PubMed ID: 1706984
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bopindolol, pindolol, and atenolol in patients with chronic obstructive lung disease.
    Schiess W; Dorow P
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S30-3. PubMed ID: 2439815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bopindolol in the treatment of moderate hypertension: a dose-response study.
    Moleur P; Peyrieux JC; Luciani J; David D; Boissel JP
    Fundam Clin Pharmacol; 1988; 2(5):431-40. PubMed ID: 2906897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of atenolol and bopindolol on circadian heart rate.
    Fitscha P; Meisner W; Tiso B
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S51-4. PubMed ID: 2439821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of chronic oral administration of a new beta-blocker, bopindolol, on serum lipoprotein concentrations and blood pressure of spontaneously hypertensive rats.
    Ishihara T; Chin WP; Yoshida Y; Sun HT; Mitomi A; Ishibashi T; Tamura K; Imai S
    Arch Int Pharmacodyn Ther; 1989; 302():145-57. PubMed ID: 2576891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bopindolol for the treatment of chronic stable angina pectoris--a clinical study of the relationship between dose and effect.
    Holmes D; Fryda-Kaurimsky Z; Krueger K
    Cardiology; 1990; 77(6):459-65. PubMed ID: 1981493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The effect of the blood pressure lowering effect of bopindolol (Sandonorm) in patients with mild and moderate hypertension].
    Zsáry A; Káldi N; Kállay K
    Orv Hetil; 1991 Sep; 132(39):2149-51. PubMed ID: 1681490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of bopindolol on left ventricular function during exercise in patients with coronary artery disease.
    Righetti A; Mérier G; Viquerat C; Ratib O; Rutishauser W
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S39-41. PubMed ID: 2439817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antihypertensive effect of isradipine on blood pressure at rest and during exercise.
    Dvorák I; Blaha M; Nĕmcová H
    Am J Hypertens; 1991 Feb; 4(2 Pt 2):144S-146S. PubMed ID: 1673616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Withdrawal of the long-acting beta blocker bopindolol is not associated with beta-adrenoceptor supersensitivity.
    Bolli P; Amann FW; Müller FB; Meyer B; Burckhardt D; Bühler FR
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S64-9. PubMed ID: 2439824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma lipid fractions during bopindolol treatment in hypertensive patients.
    van Brummelen P; Bolli P; Koolen MI; Staehelin HB; Bühler FR
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S42-4. PubMed ID: 2439818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical pharmacological studies with the long-acting beta-adrenoceptor blocking drug bopindolol.
    Aellig WH
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S12-5. PubMed ID: 2439811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacodynamic models of various beta blockers: an explanation for the long duration of action of bopindolol.
    Grevel J
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S16-9. PubMed ID: 2439812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antihypertensive activity of a new vasodilator, cadralazine, administered alone or in combination with a beta-blocker.
    Buoninconti R; Motolese M
    Int J Clin Pharmacol Ther Toxicol; 1985 Nov; 23(11):613-6. PubMed ID: 2867048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bopindolol versus metoprolol in hypertension.
    Westerman RF; Christensen C; Westheim A; Donker AJ
    Eur J Clin Pharmacol; 1986; 31(3):379-80. PubMed ID: 2878814
    [No Abstract]   [Full Text] [Related]  

  • 38. Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension--a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months rationale and study design.
    Friedrich MG; Dahlöf B; Sechtem U; Unger T; Knecht M; Dietz R;
    J Renin Angiotensin Aldosterone Syst; 2003 Dec; 4(4):234-43. PubMed ID: 14689371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of hypertension with a fixed combination of bopindolol and chlorthalidone (Sandoretic)].
    Widimský J; Lánská V; Hulínský V; Balazovjech I; Havlík V; Havránek P; Kroupa E; Nikodýmová L; Pátek F; Svítil F; Svihovcová P
    Vnitr Lek; 1996 Apr; 42(4):223-8. PubMed ID: 8693706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma lipid fractions during long-term monotherapy with the ISA-containing beta-adrenoceptor blocker bopindolol in hypertensive patients.
    Van Brummelen P; Bolli P; Koolen MI; Staehelin HB; Bühler FR
    Br J Clin Pharmacol; 1984 Jan; 17(1):86-8. PubMed ID: 6691892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.